Drug Profile
KPG 121
Alternative Names: KPG-121Latest Information Update: 16 Mar 2023
Price :
$50
*
At a glance
- Originator Kangpu Biopharmaceuticals
- Developer Accelovance; Kangpu Biopharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; CRBN protein modulators; Immunomodulators; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
- Preclinical Haematological malignancies
Most Recent Events
- 15 Mar 2023 Kangpu Biopharmaceuticals completes a phase I trial in Prostate cancer (Combination therapy, Hormone refractory, Inoperable/Unresectable, Metastatic disease) in USA (PO) before March 2023 (NCT03569280) (Kangpu Biopharmaceuticals pipeline, March 2023)
- 17 Jun 2022 Phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Inoperable/Unresectable, Metastatic disease) is ongoing in USA (PO) (NCT03569280) (Kangpu Biopharmaceuticals pipeline, June 2022)
- 17 Jun 2022 Preclinical trials in Haematological malignancies in China (PO), prior to June 2022 (Kangpu Biopharmaceuticals pipeline, June 2022)